127199-45-5

Basic information

• Product Name: Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI);(S)-7-N-BOC-AMINO-5-AZA-SPIRO[2.4]HEPTANE;(S)-tert-butyl 5-azaspiro[2.4]heptan-7-ylcarbamate;(7S)-5-Azaspiro[2.4]hept-7-ylcarbamic acid tert-butyl ester;(S)-7-tert-Butoxycarbonylamino-5-azaspiro[2.4]heptane;CarbaMic acid, N-(7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-diMethylethyl ester;tert-butyl N-[(7S)-5-azaspiro[2.4]heptan-7-yl]carbaMate;(S)-(5-Aza-spiro[2.4]hept-7-yl)-carbamic acid tert-butyl ester
• CAS NO: 127199-45-5
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• EINECS: 1312995-182-4
• Product Categories: N-BOC
• Mol File: 127199-45-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 329.029ºC at 760 mmHg
• Flash Point: 152.791ºC
• Appearance: /
• Density: 1.099g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.39±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(127199-45-5)
• EPA Substance Registry System: Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(127199-45-5)

Safety Data

• Hazardous Substances Data: 127199-45-5(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) is an organic chemical compound with the molecular formula C9H18N2O2. It is commonly known as bexolol, which is used as a beta-adrenergic blocking agent. Bexolol is a selective beta-1 blocker and is primarily used in the treatment of cardiovascular conditions such as hypertension and angina. It works by blocking the effects of adrenaline on the heart, reducing its workload and oxygen demand. Bexolol is typically administered orally in the form of tablets, and its effects usually last for 24 hours, making it a convenient option for once-daily dosing.

InChI:InChI=1/C11H20N2O2/c1-10(2,3)15-9(14)13-8-6-12-7-11(8)4-5-11/h8,12H,4-7H2,1-3H3,(H,13,14)/t8-/m1/s1

Upstream product

• 1432056-70-6 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane 
• 1268842-79-0 1-(tert-butoxycarbonyl)cyclopropane-1-carboxylic acid 
• 903900-37-8 (S)-7-amino-5-azaspiro[2.4]heptan-4-one 
• 1279116-76-5 (7S)-5-azaspiro[2.4]heptan-7-ylcarbamate tert-butyl ester 
• 144282-35-9 5-benzyl-7(S)-amino-5-azaspiro[2,4]heptane 
• 129306-05-4 ethyl 1-(2-bromoacetyl)cyclopropanecarboxylate 
• 32933-03-2 ethyl 1-acetylcyclopropanecarboxylate 
• 127199-37-5 4,7-dioxo-5-<1(R)-phenylethyl>-5-azaspiro<2.4>heptane 
• 127199-38-6 7-(S)-amino-5-<1(R)-phenylethyl>-4-oxo-5-azaspiro<2.4>heptane 
• 127199-41-1 7-(S)-amino-5-<1(R)-phenylethyl>-5-azaspiro<2.4>heptane 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 127254-12-0 sitafloxacin 
• 127199-06-8 7-((S)-7-Amino-5-aza-spiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-((1S,2R)-2-fluoro-cyclopropyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 627532-31-4 ethyl 4-[7-(S)-tert-butoxycarbonylamino-5-azaspiro[2.4]hept-5-yl]-2,5-difluoro-3-methoxybenzoylacetate 
• 167887-97-0 HSR-903 

Relevant articles and documents

Preparation method of sitafloxacin hydrate

The invention discloses a preparation method of sitafloxacin hydrate. The method comprises the following steps: taking ethyl 4-bromoacetoacetate used as a raw material, enabling ethyl 4-bromoacetoacetate to be fully reacted with 1,2-dibromoethane and preparing the obtained product into a compound II in the presence of carbonyl reduction enzyme; taking the compound II, enabling the compound II to carry out cyclization reaction with benzylamine in a solvent in the presence of cesium carbonate, enabling the obtained product to be reacted with DPPA and preparing a compound IV; reducing nitrine group of the compound IV to prepare a compound V; connecting primary amine group of the compound V with a BOC protection group to obtain a compound VI; reducing the compound VI through Pd/C, enabling theobtained product to be reacted with 8-chlorine-6,7-difluoro-1-[(1R,2s)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester to prepare a compound VIII; and carrying out deprotection of the compound VIII to obtain sitafloxacin hydrate. The sitafloxacin hydrate is few in preparation steps, simple in post-treatment and relatively high in yield.

Preparation method of sitafloxacin key intermediate

The invention discloses a preparation method of a sitafloxacin key intermediate, namely a preparation method of (7S)-t-butyloxycarboryl amino-5-azaspiro[2,4] heptane. By taking (7S)-t-butyloxycarborylamino-5-N-benzyl azaspiro[2,4] heptane as a raw material, the (7S)-t-butyloxycarboryl amino-5-azaspiro[2,4] heptane is obtained by means of devitrification after a reaction by taking palladium carbonas a catalyst and ammonium formate as a hydrogen source in an alcohol solvent. The method is simple to operate and mild in reaction, solves the problem that the triatomic ring on the spiral ring is opened successively, and meanwhile, can obtain the sitafloxacin key intermediate which is high in purity. The sitafloxacin obtained by the follow-up process is few in impurity, high in purity and suitable for the demand on industrial production.

Processes for preparation of bicyclic compounds and intermediates therefor

A process for preparing intermediate compound (VII), compound (VIII) and compound (XIV) which will be raw materials for the synthesis of a synthetic antibactrial compound, via compound (I) or compound (X) and then, compound (II), the compounds each being shown below; and novel compounds useful for the preparation.